Phase 2 Alzheimer's Disease Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged between 60 and 100 years old at the start of the study
• People who have been diagnosed with Alzheimer's Clinical Syndrome or Alzheimer's Dementia
• People who are willing to participate and are able to go through the consent process
• People who have a caregiver or support person who can attend all study visits with them
• People who have a known backup decision-maker who can attend the consent visit (this can be the same person as the caregiver/support person above)
• People whose memory test score (MMSE) falls between 18 and 26 at screening
• People whose depression screening score (GDS) is below 6 at screening
• People who are either: currently taking a memory-enhancing medication (called a cholinesterase inhibitor) for at least 2 months, have tried one in the past but stopped with no plans to retry, or have no plans to start one during the study
• People who have not changed their use of medications for depression, anxiety, ADHD, or psychosis in the 2 weeks before the study begins

Who may not be able to join:

• People who, or whose backup decision-maker, are unwilling or unable to give informed consent
• People who are currently pregnant or may become pregnant
• People whose memory or thinking problems are caused by something other than Alzheimer's Disease
• People diagnosed with severe dementia (a CDR score above 2.0) at the start of the study
• People with a history of substance use disorder that is not currently in sustained remission
• People who have misused substances (not including nicotine or caffeine) in the past 6 months
• People with a history of stroke, traumatic brain injury with loss of consciousness, epilepsy, Huntington's disease, Parkinson's disease, or other major neurological conditions
• People with a personal history of seizures, or whose immediate family members (parent, sibling, or child) have a history of seizure disorders
• People with poorly controlled high blood pressure, heart disease, or problems with blood flow to the brain
• People with any other significant active medical, neurological, or psychiatric condition that affects thinking or the ability to safely take part in the study
• People who are not fluent in English (at a native or near-native level)
• People for whom MRI or TMS procedures are not safe, including those with claustrophobia, metal in the body that is incompatible with MRI or of unknown type (including certain facial tattoos), surgery within the past 60 days, certain implants, or previous abnormal MRI results (dental fillings are generally not an issue — confirm with trial site)
• People who have previously received TMS (transcranial magnetic stimulation) treatment
• People currently enrolled in another memory-enhancement study
• People whose memory medication dose has changed in the past 2 months, or for whom a dose change is planned during the study
• People who have previously been treated with certain Alzheimer's antibody medications, including lecanemab, aducanumab, donanemab, or similar treatments
• People currently taking, or who have taken in the past 2 weeks, certain types of medications including: anticholinergic drugs (e.g., tolterodine, benztropine), sedating antihistamines (e.g., diphenhydramine), medications with strong anticholinergic or antihistamine effects (e.g., certain antidepressants such as tricyclics or mirtazapine); note that benzodiazepines, anti-epileptic medications, and antipsychotic medications will be assessed individually on a case-by-case basis (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.